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Summary The oral loading test with tetrahydrobiopterin
(BH4) is used to discriminate between variants of hyper-
phenylalaninaemia and to detect BH4-responsive patients.
The outcome of the loading test depends on the genotype,
dosage of BH4, and BH4 pharmacokinetics. A total of 71
patients with hyperphenylalaninaemia (mild to classic) were
challenged with BH4 (20 mg/kg) according to different pro-
tocols (1 × 20 mg or 2 × 20 mg) and blood BH4 concen-
trations were measured in dried blood spots at different time
points (T0, T2, T4, T8, T12, T24, T32 and T48 h). Maximal
BH4 concentrations (median 22.69 nmol/g Hb) were mea-
sured 4 h after BH4 administration in 63 out of 71 patients.
Eight patients presented with maximal BH4 concentrations
∼44% higher at 8 h than at 4 h. After 24 h, BH4 blood con-
centrations dropped to 11% of maximal values. This profile
was similar using different protocols. The following phar-
macokinetic parameters were calculated for BH4 in blood:
tmax = 4 h, AUC (T0−32) = 370 nmol × h/g Hb, and t1/2
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for absorption (1.1 h), distribution (2.5 h), and elimination
(46.0 h) phases. Maximal BH4 blood concentrations were not
significantly lower in non-responders and there was no corre-
lation between blood concentrations and responsiveness. Of
mild PKU patients, 97% responded to BH4 administration,
while one was found to be a non-responder. Only 10/19 pa-
tients (53%) with Phe concentrations of 600–1200 μmol/L
responded to BH4 administration, and of the patients with
the severe classical phenotype (blood Phe > 1200 μmol/L)
only 4 out of 17 patient responded. An additional 36 patients
with mild hyperphenylalaninaemia (HPA) who underwent
the combined loading test with Phe+BH4 were all respon-
ders. Slow responders and non-responders were found in all
groups of HPA.
Abbreviations
AUC area under the curve
BH4 tetrahydrobiopterin
HPA hyperphenylalaninaemia
PAH phenylalanine hydroxylase
PKU phenylketonuria
t1/2 half-life
Introduction
The loading test with tetrahydrobiopterin (BH4) is an essen-
tial and integral part of the differential diagnosis for hyper-
phenylalaninaemia (HPA) (Blau et al 2001). This test dis-
criminates between BH4 responders and non-responders and
is particularly important for detection of patients with BH4-
responsive phenylalanine hydroxylase (PAH; EC 1.14.16.1)
deficiency (Blau and Erlandsen 2004). In BH4 responders,
blood phenylalanine (Phe) declines 4–24 h after BH4 ad-
ministration (20 mg/kg body weight), with almost complete
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Fig. 1 Definition of the BH4
responsiveness after oral
administration of BH4 (20
mg/kg). RR: rapid responder;
MR: moderate responder; SR:
slow responder; NR:
non-responder; ND not defined
normalization after 4–8 h in patients with BH4 deficiency.
BH4-responsive PAH patients were initially defined as show-
ing a decrease of blood Phe concentrations of 30% after 8 h
and 30–50% after 24 h (Bernegger and Blau 2002) and most
of them belong to the group of mild HPA and mild and mod-
erate phenylketonuria (PKU; OMIM 262600) (Desviat et al
2004; Fiori et al 2005; Kure et al 1999; La¨ssker et al 2002;
Lindner et al 2003; Lu¨cke et al 2003; Matalon et al 2004;
Mitchell et al 2005; Muntau et al 2002; Perez-Duenas et al
2004; Spaapen et al 2001; Steinfeld et al 2003; Trefz and
Blau 2003). Sensitivity of the test was further improved by
multiple administrations of BH4 and by longer observation
time (Fiege et al 2005; Shintaku et al 2004). Efficiency and
interpretation of the loading test depends on several factors
such as amount of administered BH4, severity of HPA, di-
etary management, and genotype. The pharmacokinetics of
BH4 was suggested as an additional factor affecting the load-
ing test; however, this was never investigated in patients with
PKU (Fiege et al 2004).
The aim of this study was to estimate basic kinetic pa-
rameters for BH4 in blood after administration of BH4 and
following the combined Phe+BH4 loading test, and to cor-
relate the BH4 concentrations in blood with the outcome of
the test.
Materials and methods
Patients
A total of 71 HPA patients in whom BH4 deficiency had
been excluded were loaded with a single dose of BH4 (20
mg/kg); 35 of them presented with basal blood Phe con-
centrations <600 μmol/L, 19 with Phe concentrations of
600–1200 μmol/L, and 17 with Phe concentrations >1200
μmol/L. In 11 patients with blood Phe concentrations of 278–
1575 μmol/L the standard test was extended by the adminis-
tration of another 20 mg/kg BH4 after 24 h. An additional 36
patients with basal Phe concentrations of 384–739 μmol/L
underwent a combined Phe (100 mg/kg) and BH4 (20 mg/kg)
loading test.
Mutation analysis was done in only a few patients and
was not included in this study. The study was performed
after a formal consensus of patients or their parents and in
accordance with the Helsinki recommendations 1989.
Loading test
The single BH4 test, the extended test, and the combined
Phe+BH4 loading test were performed as described pre-
viously using the 6R-BH4 (Schircks Laboratories, Jona,
Switzerland) (Blau and Erlandsen 2004; Fiege et al 2005). In
patients loaded with a single dose of BH4 (20 mg/kg), blood
was collected at times T0, T4, T8 and T24 h. In 45 of them ad-
ditional blood collections were done at T2, T12 and T48 h. In
patients loaded with 2 × 20 mg/kg BH4, blood was collected
at T0, T4, T8, T24, T32 and T48 h, and in patients loaded with
Phe+BH4 the following blood collections were performed:
T−3 (Phe administration), T0 (BH4 administration), T4, T8
and T24 h.
The following criteria were used to define BH4-
responsiveness over 24 h (Fiege et al 2005): ’rapid respon-
der’, reduction of blood Phe by ≥30% at T8, and ≥50% at
T24; ’moderate responder’, reduction of blood Phe by ≥20%
at T8, and ≥30% at T24; ’slow responder’, reduction of blood
Phe by <20% at T8, and ≥20% at T24 (Fig. 1).
BH4 and Phe in blood
BH4 was measured in dried blood spots according to the
method of Zurflu¨h and colleagues (2005) and calculated as
the sum of total biopterin and pterin (nmol BH4/g Hb). The
following protocol was used: For each measurement, four
blood circles (Ø6 mm) were cut out and pterins were ex-
tracted with 250 μL of 20 mmol/L HCl and placed in an ultra-
sonic bath for 30 s. Pterins were extracted by mixing the filter
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Fig. 2 BH4 concentrations in
blood after oral administration
of BH4 (20 mg/kg) in 47
patients with HPA. — Median,
 25th–75th percentiles; ⊥ 5th
percentile; T 95th percentile; +
min/max
spot solution for 10 min at room temperature. The extract was
centrifuged at 1800 × g for 5 min at room temperature. Clear
supernatatant (60 μL) was used for analysis of haemoglobin
on the haematology analyser Sysmex KX-21N (Sysmex Cor-
poration, Japan). The remaining supernatant was ultrafiltered
on Ultrafree (NMWL 10000; Millipore) at 5000 × g for
15 min. Pterins were analysed in clear filtrate by HPLC and
fluorescence detection without prior oxidation (Zurflu¨h et al
2005).
Phe was measured using standard ion-exchange chro-
matography of amino acids or tandem-mass spectrometry.
Statistical analyses
WinSTAT for Excel (v. 2003.1) was used for descriptive
statistics and for regression analysis. Pharmacokinetic pa-
rameters were calculated using the PK Solutions software, v.
2.0 (Summit Research Services, Montrose, CO).
Results
BH4 kinetics in blood
In 63 out of 71 patients with HPA loaded with 20 mg/kg BH4,
blood BH4 concentrations reached highest values after 4 h
(median = 22.65 nmol/g Hb; 5th–95th percentiles = 10.07–
49.97 nmol/g Hb). Four hours later (T8) BH4 concentrations
decreased by 42% (median = 13.61 nmol/g Hb; 5th–95th
percentiles = 5.25–31.63 nmol/g Hb) and after 24 h BH4
concentrations were only 11% of maximal values (median =
2.29 nmol/g Hb; 5th–95th percentiles = 0.67–5.35 nmol/g
Hb). In 8 out of 71 patients, blood BH4 concentrations were
∼44 % higher at 8 h than values at 4 h after administration
and the highest single BH4 value was 96.39 nmol/g Hb at
T4 h.
In 45 of the above patients the blood BH4 profile was inves-
tigated over 32 h after BH4 administration (20 mg/kg) with
additional time points at T2, T12 and T32 h (Fig. 2). Two hours
after BH4 administration (median = 16.30 nmol/g Hb; 5th–
95th percentiles = 6.84–28.44 nmol/g Hb) blood concen-
trations reached about 70% of the maximal concentrations
found after 4 h. At 12 h (median = 6.15 nmol/g Hb; 5th–95th
percentiles = 2.90–12.38 nmol/g Hb) and 32 h (median =
2.03 nmol/g Hb; 5th–95th percentiles = 0.51–5.47 nmol/g
Hb) BH4 blood concentrations were lower than those at 8 h
(47% and 15%, respectively).
In 11 patients the protocol was extended to a second ad-
ministration of BH4 (20 mg/kg) after 24 h (Fig. 3). Blood
was collected 8 (T32) and 24 (T48) hours after the second ad-
ministration and compared with T8 concentrations for BH4
in blood (median = 15.37 nmol/g Hb; 5th–95th percentiles
= 7.05–54.02 nmol/g Hb); T32 values were 17% lower (me-
dian = 12.80 nmol/g Hb; 5th–95th percentiles = 7.41–38.54
nmol/g Hb). There was no significant difference in BH4 con-
centrations at T24 and T48 h.
Thirty-six patients with blood Phe concentrations of <336
μmol/L were loaded first with Phe (100 mg/kg) and three
hours later with BH4 (20 mg/kg), and blood samples were
collected before Phe administration (T−3), before BH4 ad-
ministration (i.e. 3 h after Phe loading; T0), and 4, 8 and 24 h
after BH4 administration (T4−24) (Fig. 4). BH4 concentra-
tions in blood increased in 26/36 patients after Phe admin-
istration by 111% (BH4 at T−3, median = 0.30 nmol/g Hb;
5th–95th percentiles = 0.12–2.77 nmol/g Hb; BH4 at T0,
median = 0.52 nmol/g Hb; 5th–95th percentiles = 0.16–
4.43 nmol/g Hb). The following profile of BH4 kinetics
was similar as the one described for a single BH4 admin-
istration, with maximal blood concentrations at T4 (median
= 22.01 nmol/g Hb; 5th–95th percentiles = 10.40–46.58
nmol/g Hb), 25% lower concentrations at T8 (median =
16.46 nmol/g Hb; 5th–95th percentiles = 4.66–33.49 nmol/g
Hb), and 90% lower concentrations at T24 (median = 2.09
nmol/g Hb; 5th–95th percentiles = 0.55–6.84 nmol/g Hb). In
6 subjects maximal BH4 concentrations were reached after
8 h.
Springer
728 J Inherit Metab Dis (2006) 29:725–731
Table 1 Summary of BH4 loading tests (20 mg/kg) in 71 patients with PAH deficiency
Initial blood Phe concentrations
n <600 μmol/L (n = 35) 600–1200 μmol/L (n = 19) >1200 μmol/L (n = 17)
Responder (total) 48 34 10 4
Rapid responder 34 26 6 2
Moderate responder 10 7 3 0
Slow responder 4 1 1 2
Non-responder 21 1 8 12
Not defined 2 0 1 1
Based on data obtained over 32 h after a single BH4 ad-
ministration (20 mg/kg) in 45 patients with HPA, basic phar-
macokinetic parameters were calculated: tmax was 4 h, AUC
(T0−32) was 370 nmol × h/g Hb, and t1/2 for absorption,
distribution, and elimination phases was 1.1, 2.5, and 46.0 h,
respectively.
Responsiveness to BH4
Table 1 summarizes the results of the loading test with
20 mg/kg BH4 in patients with HPA. Responsiveness was
calculated according to criteria defined in Fig. 1. 34/35
patients (97%) with basal blood Phe concentrations <600
μmol/L responded to BH4 administration, one patient was
found to be a non-responder. Only 10/19 patients (53%)
with basal blood Phe concentrations of 600–1200 μmol/L
responded to BH4 administration, and of the patients with
the severe classical phenotype (blood Phe > 1200 μmol/L)
only four patients responded (24%), and two of them were
slow responders (Fig. 5). The lower the Phe at T0 the higher
the probability that a patient will respond to BH4. Two pa-
tients could not be assigned to the above-mentioned criteria;
one would have been positioned somewhere between mod-
erate and slow responder and the other was at the level of a
Fig. 3 BH4 concentrations in
blood after oral administration
of BH4 (2 × 20 mg/kg) in 11
patients with HPA. Second
dosage of BH4 was administered
24 h after the first application.
— Median,  25th–75th
percentiles; ⊥ 5th percentile; T
95th percentile; + min/max
Fig. 4 BH4 concentrations in
blood after oral administration
of Phe (100 mg/kg) and BH4 (20
mg/kg) in 36 patients with mild
HPA. BH4 was administered 3 h
after Phe application. —
Median,  25th–75th
percentiles; ⊥ 5th percentile; T
95th percentile; + min./max
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Fig. 5 Correlation between Phe
decline in blood 24 h after
administration of BH4
(20 mg/kg) and basal Phe levels
in 71 patients with HPA. 
Rapid responder; ; moderate
responder; ∗ slow responder; ·
non-responder
Fig. 6 Correlation between Phe
decline in blood 24 h after
administration of BH4 (20
mg/kg) and maximal BH4 levels
in 71 patients with HPA
rapid responder after 8 h but dropped at 24 h below the level
of a slow responder.
All 36 patients who underwent the combined loading
test with Phe+BH4 were classified as responders (data not
shown).
In order to demonstrate whether absorption of BH4 may
affect the outcome of the loading test, maximal blood BH4
concentrations were compared with responsiveness to BH4,
but no correlation was found (Fig. 6). Highest maximal blood
BH4 concentrations were found in two rapid responders.
Discussion
Extensive pharmacokinetic studies of BH4 have been per-
formed in animal models (Hayashi et al 1992), but only a
few parameters are known from studies in humans (Fiege and
Blau 2006). Some pharmacokinetic parameters are known
from oral administration of BH4 tablets to healthy adult hu-
man volunteers and might provide details on pharmacologi-
cal response to BH4 therapy (Fiege et al 2004). Plasma con-
centrations of BH4 and total biopterin were assessed after
oral administration of 6R-BH4 at different doses to different
healthy subjects and preliminary pharmacokinetic parame-
ters have been determined (Fiege et al 2004). The plasma
profile of total biopterin after oral administration exhibited
first-order kinetics, showing a fast absorption phase (T0–T4),
a rapid decline (T4–T10) corresponding to the absorption and
distribution phase, followed by a slower decline in the final
elimination phase (T10–T33 h). Total biopterin concentrations
in plasma have been studied after administration of different
doses (10 and 20 mg/kg) to one healthy adult subject (Fiege
et al 2004). Maximal plasma concentrations in this subject
were reached 4 h after the 10 mg/kg dose and 3 h after the
20 mg/kg dose, at concentrations of 258.7 and 441.7 nmol/L,
respectively. The AUC0−10 after administration of 20 mg/kg
was 1.6 times higher than the AUC after the 10 mg/kg dosage
(3046 vs 1958 nmol h/L). Based on these data, the elimina-
tion kinetics seem to be only slightly faster at higher plasma
concentrations (tmax = 4.2 h vs 5.1 h) (Fiege et al 2004).
Very little is known about BH4 pharmacokinetics in pa-
tients with HPA. Shintaku and colleagues (2005) reported
plasma biopterin concentrations in two patients with HPA
who underwent a single BH4 loading test (10 mg/kg) at dif-
ferent ages. In both patients plasma biopterin concentrations
were ∼100% higher at an early age (<1 month) compared
with concentratiuons measured at the age of 2 months. Also,
biopterin concentrations peaked at 4 h at the age of 1 month,
compared with maximal concentrations at 2 h at the age of
2 months. The authors suggested that BH4 responsiveness in
the same individual or the same genotype may correlate with
biopterin concentration, but in different genotypes this might
not be the case (Shintaku et al 2005).
We were not able to see any statistical difference between
different age groups in our patients (data not shown). Simi-
larly to what was described for healthy controls (Fiege et al
2004), blood BH4 peaked at 4 h in 90% of patients with HPA.
This profile was consistent regardless of whether patients
were loaded with one or two BH4 doses or after Phe ad-
ministration (Figs. 2–4). Two hours after BH4 administra-
tion, blood concentrations were about 70% of the maximal
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BH4 concentrations, indicating a very fast absorption phase
(t1/2 = 1.1 h). In our patients, oral administration of BH4 re-
sulted in a fast distribution phase (t1/2 = 2.5 h), followed by
a slow elimination phase (t1/2 = 46.0 h). Thus, although a
single BH4 administration may be sufficient for the interpre-
tation of the loading test, additional dosages can potentate the
effect and increase the sensitivity (Fiege et al 2005; Shintaku
et al 2004).
Data from the combined Phe+BH4 loading test show that
administration of Phe (100 mg/kg) almost doubled blood
BH4 concentrations after 3 h in 72% of patients (Fig. 4). This
is consistent with previous findings that biopterin concentra-
tions in urine or plasma correlate with blood phenylalanine
concentrations (Dhondt and Farriaux, 1982; Ponzone et al
1993) but have no consequences on the outcome of the load-
ing test. Phenylalanine administration does not influence BH4
concentrations upon oral BH4 administration. As expected,
all patients in this group were classified as responders and
one should question how useful this test is. Factors such as
spontaneous Phe elimination (Desviat et al 2004) or daily
fluctuations (Leuzzi et al 2006) may influence the interpre-
tation, and from our experience the combined loading test is
not recommended. It can be only used in patients who are
already on a strict low-phenylalanine diet with normalized
blood phenylalanine concentrations.
One of the main goals of this study was to evaluate
the effect of blood BH4 concentrations on the outcome of
the loading tests. Recently we described a single case with
HPA (BH4-responsive genotype) showing intra-individual
variations in BH4 absorption on two occasions, which re-
sulted in different BH4 blood concentrations and influenced
the responsiveness (Zurflu¨h et al 2005). We were not able to
repeat the loading test in non-responders in this study, but
maximal BH4 blood concentrations were not significantly
lower in this group of patients. Indeed, maximal BH4 blood
concentrations were only 3% lower in non-responders than in
all responders, and slow responders had 7% and 42% higher
concentrations than moderate or rapid responders, respec-
tively (data not shown).
With regard to the responsiveness to BH4, our data confirm
previous observations that rapid responders belong mainly to
the groups of mild HPA and mild PKU, and that patients with
classical PKU show either only a slow response or none at all
(Fig. 5). Nevertheless, slow responders and non-responders
were found in all groups of HPA.
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